- Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
- Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
- Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
- It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation
Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability.
Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more.
In March 2022, the company announced that it would begin a human clinical study, NIC-H22-1, focused on oral nicotine alternatives to replace smoking. The study would involve 36 participants and compare DehydraTECH’s nicotine pouch performance with existing brands on the market. In a previous animal study, the DehydraTECH-nicotine proved to deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls (https://nnw.fm/7DM6C).
Lexaria is also in the process of a clinical human study, HYPER-H21-4, to determine the effectiveness of DehydraTECH-CBD for hypertension treatment. Involving 60 participants, this ranks as one of the most comprehensive studies undertaken by Lexaria and is a significant step for the company as it seeks Investigational New Drug (“IND”) approval by the United States Food and Drug Administration (“FDA”). Results are expected in Q3 2022 (https://nnw.fm/F8HZV).
Lexaria has also made significant progress using its technology for the enhanced delivery of antiviral drugs. On April 26, 2022, it received its 25th patent granted worldwide in what Chris Bunka, the Chief Executive Officer (“CEO”) of the company, referred to as “Another validation of the versatility of our DehydraTECH drug delivery technology” (https://nnw.fm/rqgY0).
Earlier in the year, Lexaria also announced commencing the first phase of its epilepsy research program, EPIL-A21-1. The study would assess the seizure-inhibiting activity of CBD administered via the company’s DehydraTECH technology. More specifically, Lexaria aimed to compare its technology to the only FDA-approved CBD-based seizure medication Epidiolex, used to treat seizures associated with two rare forms of pediatric epilepsy- Lennox-Gastaut syndrome and Dravet syndrome (https://nnw.fm/yc959).
All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so, it is looking to tap into various markets, including but not limited to oral cannabinoids, oral mucosal nicotine, antivirals, human hormones, dementia, rheumatoid disease and diabetes.
Lexaria’s management hopes that before the end of the 2022 calendar year, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation to steer the conversation forward and allow for the greater adoption of DehydraTECH.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork
